Join to View Full Profile
4505 Beech StreetBellaire, TX 77401
Phone+1 713-794-4392
Dr. Daver is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- Baylor College of MedicineFellowship, Hematology and Medical Oncology, 2008 - 2011
- Baylor College of MedicineResidency, Internal Medicine, 2005 - 2008
- Grant Medical CollegeClass of 2004
Certifications & Licensure
- FL State Medical License 2021 - Present
- TX State Medical License 2011 - 2025
- OK State Medical License 2020 - 2021
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia Start of enrollment: 2001 Mar 01
- Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm Start of enrollment: 2013 Mar 13
- Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome Start of enrollment: 2013 Jul 18
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsClinico-Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies.Jayastu Senapati, Sanam Loghavi, Jennifer Marvin-Peek, Guillermo Garcia-Manero, Tapan M Kadia
American Journal of Hematology. 2025-05-01 - Blood-Based Proteomic Profiling Identifies OSMR as a Novel Biomarker of AML Outcomes.Patrick K Reville, Bofei Wang, Jennifer Marvin-Peek, Bin Yuan, Yu-An Kuo
Blood. 2025-04-03 - Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges.Jayastu Senapati, Tapan M Kadia, Naval G Daver, Courtney D DiNardo, Gautam Borthakur
Cancer. 2025-04-01
Abstracts/Posters
- Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic SyndromesNaval G. Daver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid LeukemiaNaval G. Daver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR)Naval G. Daver, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- A Phase 1 Study of Milademetan in Combination with Quizartinib in Patients with Newly Diagnosed (ND) or Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML)61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and/or Azacitidine for Patients with CD123-P...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Treating Acute Myeloid Leukemia: Case Challenges and Emerging Therapies61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Join now to see all
Press Mentions
- MD Anderson Research Highlights for December 18, 2024December 18th, 2024
- ASH: Monoclonal Antibody Therapy Improves Survival in Cancer-Associated Hyper-Inflammatory DisorderDecember 9th, 2024
- Researchers Discover an Origin of Idiopathic AutismDecember 4th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: